Allergan acquisition supports GSK growth
This article was originally published in Scrip
Executive Summary
A possible GlaxoSmithKline acquisition of Allergan could boost GSK's growth in annual free cash flow and dividends between 2008 and 2014, analysts say. This follows recent speculation that GSK might be a potential buyer for the US company (scripnews.com, March 25th, 2009).